Sector
PharmaceuticalsOpen
₹8,602Prev. Close
₹8,607.65Turnover(Lac.)
₹1,880.18Day's High
₹8,748.5Day's Low
₹8,463.2552 Week's High
₹9,059.0552 Week's Low
₹4,800.15Book Value
₹307.76Face Value
₹2Mkt Cap (₹ Cr.)
21,231.63P/E
128.36EPS
67.05Divi. Yield
0.28The approval is for two dosing forms: 120 mg/2.4 ml and 500 mg/10 ml.
The company may import the powder form of sodium zirconium cyclosilicate for preparation of oral suspension as Lokelma in 5 g and 10 g formulation.
As per the reported property consultants, the company has issued a global mandate for selecting candidates for the said land deal.
It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.
This combination drug is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 706.92 | 583.69 | 506.39 | 451.17 |
Net Worth | 711.92 | 588.69 | 511.39 | 456.17 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 805.6 | 813.56 | 831.81 | 571 |
yoy growth (%) | -0.97 | -2.19 | 45.67 | 5.01 |
Raw materials | -311.96 | -294.95 | -305.23 | -181.09 |
As % of sales | 38.72 | 36.25 | 36.69 | 31.71 |
Employee costs | -230.21 | -219.54 | -216.7 | -153.53 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 83.04 | 127.09 | 113.97 | 43.8 |
Depreciation | -16.95 | -20.13 | -18.58 | -14.74 |
Tax paid | -21.44 | -33.79 | -41.76 | -17.89 |
Working capital | 57.86 | 101.15 | 103.65 | 52.76 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -0.97 | -2.19 | 45.67 | 5.01 |
Op profit growth | -36.38 | 12.23 | 160.74 | 25.31 |
EBIT growth | -34.47 | 11.35 | 162.8 | 23.38 |
Net profit growth | -33.97 | 29.2 | 178.69 | 29.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 132.17 | 4,16,392.59 | 1,181.05 | 0.78 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 73.93 | 1,53,257.67 | 594 | 0.52 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.02 | 1,16,434.16 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 60.01 | 1,09,468.65 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 51.7 | 99,973.97 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Narayan K Seshadri
Non-Exec. & Independent Dir.
Revathy Ashok
Non-Exec. & Independent Dir.
Shilpa Divekar Nirula
Managing Director
Sanjeev Panchal
Non Executive Director
Hooi Bien Chuah
Non Executive Director
Sylvia Lorena Varela Ramon
Executive Director
Bhavana Agrawal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Astrazeneca Pharma India Ltd
Summary
AstraZeneca Pharma India (APIL) was incorporated on July 11, 1979. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company. The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology.AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Companys issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. AstraZeneca Pharmaceuticals AB Sweden. AstraZeneca Pharma India Limited (the Company) is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC, United Kingdom.The company expanded the installed capacity of Injectables during the year 2001 by 0.20 crores (Nos) and with this expansion the total capacity has been increased to 2.40 crores (Nos).The Companys marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commiss
Read More
The Astrazeneca Pharma India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹8492.65 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astrazeneca Pharma India Ltd is ₹21231.63 Cr. as of 01 Apr ‘25
The PE and PB ratios of Astrazeneca Pharma India Ltd is 128.36 and 31.67 as of 01 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Astrazeneca Pharma India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Astrazeneca Pharma India Ltd is ₹4800.15 and ₹9059.05 as of 01 Apr ‘25
Astrazeneca Pharma India Ltd's CAGR for 5 Years at 30.84%, 3 Years at 48.72%, 1 Year at 61.54%, 6 Month at 8.00%, 3 Month at 17.32% and 1 Month at 28.50%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.